Back To: Home : Featured Technology : PCR/qPCR

CLICK HERE FOR WHAT'S NEW IN:
 

QIAGEN acquires artus GmbH
July 2005
EDIT CONNECT

SHARING OPTIONS:

VENLO, The Netherlands—Qiagen N.V., a provider of enabling technologies and products for the separation, purification and handling of nucleic acid and proteins announced in late May that its wholly owned subsidiary Qiagen GmbH entered into an agreement to acquire artus GmbH, a provider of PCR-based molecular diagnostic tests for pathogenenic, genotyping and pharmacogenomic testing.
 
artus focuses on selling its diagnostic assays as OEM products to leading diagnostic companies including Abbott Laboratories. Like Qiagen, artus has made significant moves towards regulatory standardization. The artus RealArt assay range was developed for use on a variety of open architecture detection platforms including the Roche LightCycler, the ABI Taqman and the RotorGene  from Corbett Research.
 
artus' portfolio spans over 60 assays including 30 CE marked assays for detection of a variety of viral and bacterial pathogens such as SARS, Herpes simplex virus -1/-2, Epstein-Barr Virus (EBV), West Nile Virus, malaria and Salmonella.
 
Code: E070514

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.